{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Prednisone+Oral+Product&page=3", "query": { "intervention": "Prednisone Oral Product", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 110, "total_pages": 11, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Prednisone+Oral+Product&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Prednisone+Oral+Product&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-02T16:18:46.974Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04726332", "title": "Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasm Malignant", "Epithelial Ovarian Cancer", "Triple Negative Breast Cancer", "Hormone Receptor Positive Breast Carcinoma", "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "XL102", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2021-02-10", "completion_date": "2024-05-02", "has_results": false, "last_update_posted_date": "2024-05-14", "last_synced_at": "2026-10-02T16:18:46.974Z", "location_count": 5, "location_summary": "Atlanta, Georgia • Boston, Massachusetts • Dallas, Texas + 2 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04726332" }, { "nct_id": "NCT00296244", "title": "Steroid Free Immunosuppression in Liver Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Liver Cirrhosis", "Liver Transplant Disorder" ], "interventions": [ { "name": "Steroids", "type": "DRUG" }, { "name": "Basiliximab", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Enteric-coated Mycophenolic acid (EC-MPA)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "72 Years", "sex": "ALL", "summary": "18 Years to 72 Years" }, "enrollment_count": 40, "start_date": "2006-02", "completion_date": "2008-06", "has_results": true, "last_update_posted_date": "2012-11-19", "last_synced_at": "2026-10-02T16:18:46.974Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00296244" }, { "nct_id": "NCT06315309", "title": "Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "GVHD,Acute", "Acute Leukemia", "Myelodysplastic Syndromes", "Myeloproliferative Disorders" ], "interventions": [ { "name": "ATG Combined with Tacrolimus and Mini Methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 29, "start_date": "2025-04-15", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2025-10-08", "last_synced_at": "2026-10-02T16:18:46.974Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT06315309" }, { "nct_id": "NCT06676579", "title": "Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "IgA Nephropathy (IgAN)" ], "interventions": [ { "name": "Avacopan", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Methylprednisolone (drug)", "type": "DRUG" }, { "name": "Prednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2025-06-09", "completion_date": "2029-03-02", "has_results": false, "last_update_posted_date": "2025-10-03", "last_synced_at": "2026-10-02T16:18:46.974Z", "location_count": 2, "location_summary": "Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06676579" }, { "nct_id": "NCT01650545", "title": "Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Disorder Related to Lung Transplantation", "Bronchiolitis Obliterans", "Decreased Immunologic Activity", "Chronic Rejection of Lung Transplant" ], "interventions": [ { "name": "Liposomal aerosol cyclosporine", "type": "DRUG" }, { "name": "standard immune suppression, oral", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2012-07", "completion_date": "2019-11", "has_results": true, "last_update_posted_date": "2023-06-01", "last_synced_at": "2026-10-02T16:18:46.974Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01650545" }, { "nct_id": "NCT02531633", "title": "Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Giant Cell Arteritis" ], "interventions": [ { "name": "Sirukumab", "type": "DRUG" }, { "name": "Placebo to match sirukumab", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Placebo to match prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 161, "start_date": "2015-10-16", "completion_date": "2018-03-21", "has_results": true, "last_update_posted_date": "2019-07-31", "last_synced_at": "2026-10-02T16:18:46.974Z", "location_count": 13, "location_summary": "Aurora, Colorado • Boca Raton, Florida • Naples, Florida + 9 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Naples", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02531633" }, { "nct_id": "NCT00060346", "title": "Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Eastern Cooperative Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2004-10-05", "completion_date": "2012-08", "has_results": true, "last_update_posted_date": "2023-06-29", "last_synced_at": "2026-10-02T16:18:46.974Z", "location_count": 153, "location_summary": "Little Rock, Arkansas • Lewes, Delaware • Newark, Delaware + 96 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Lewes", "state": "Delaware" }, { "city": "Newark", "state": "Delaware" }, { "city": "Aurora", "state": "Illinois" }, { "city": "Joliet", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00060346" }, { "nct_id": "NCT00035555", "title": "Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Graft Rejection", "Kidney Transplantation", "Renal Transplantation" ], "interventions": [ { "name": "Belatacept", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Mycophenolate mofetil (MMF)", "type": "DRUG" }, { "name": "Corticosteroids", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 230, "start_date": "2001-03", "completion_date": "2012-07", "has_results": true, "last_update_posted_date": "2014-01-13", "last_synced_at": "2026-10-02T16:18:46.974Z", "location_count": 12, "location_summary": "San Francisco, California • Atlanta, Georgia • Baltimore, Maryland + 9 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00035555" }, { "nct_id": "NCT01777152", "title": "ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anaplastic Large-Cell Lymphoma", "Non-Hodgkin Lymphoma", "T-Cell Lymphoma" ], "interventions": [ { "name": "brentuximab vedotin", "type": "DRUG" }, { "name": "doxorubicin", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 452, "start_date": "2013-01-31", "completion_date": "2020-10-02", "has_results": true, "last_update_posted_date": "2021-11-30", "last_synced_at": "2026-10-02T16:18:46.974Z", "location_count": 32, "location_summary": "Gilbert, Arizona • Duarte, California • Stanford, California + 24 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01777152" }, { "nct_id": "NCT04477512", "title": "Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Hormone Refractory Prostate Cancer" ], "interventions": [ { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Abiraterone acetate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Peripheral blood collection", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 18, "start_date": "2021-02-19", "completion_date": "2025-09-10", "has_results": false, "last_update_posted_date": "2025-11-12", "last_synced_at": "2026-10-02T16:18:46.974Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04477512" } ] }